Catalog No.
Product Name
Application
Product Information
Citations
-
JAK Inihibitor
AC-430 hydrobromide is a potent JAK2 inhibitor that specifically targets the Janus kinase family, playing a crucial role in the signaling pathways of hematopoiesis. This compound demonstrates significant biological activity in the context of myeloproliferative disorders and certain cancers, making it a valuable reagent for research in these areas. Its inhibition of JAK2 provides insights into therapeutic strategies for related malignancies and inflammatory conditions. -
JAK Inhibitor
JAK-IN-10 is a selective Janus kinase (JAK) inhibitor that modulates inflammatory pathways by inhibiting JAK signaling. It is particularly valuable in the study of dry eye disorders, providing insights into the underlying mechanisms of inflammation. Additionally, JAK-IN-10 features an alkyne functional group and is suitable for click chemistry applications, enabling efficient copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing compounds. This property enhances its utility in chemical biology and medicinal chemistry research. -
JAK Inhibitor
Frevecitinib is a potent pan-JAK inhibitor, targeting JAK1, JAK2, JAK3, and TYK2. This compound is useful for investigating mechanisms involved in asthma and other respiratory conditions, including chronic obstructive pulmonary disease (COPD). Its ability to modulate JAK signaling pathways makes it a valuable tool in research focused on inflammatory diseases and immune response. -
JAK2 Inhibitor
JAK-IN-35 is a selective JAK2 inhibitor that targets the Janus kinase 2 enzyme. This compound demonstrates significant anti-proliferative activity in various cancer cells, making it a valuable tool for cancer research. Its ability to modulate JAK2 signaling pathways can aid in the exploration of therapeutic strategies for malignancies driven by aberrant JAK2 activity. -
JAK Inhibitor
JAK-IN-26 is an orally active Janus kinase (JAK) inhibitor that effectively targets the JAK-STAT signaling pathway. It demonstrates significant inhibitory activity on IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells, with an IC50 value of 17.2 nM. This compound is valuable for research applications focused on cytokine signaling, immune response modulation, and the study of JAK-related signaling pathways in various disease contexts. -
JAK1 Inhibitor
JAK-IN-14 is a selective inhibitor of Janus kinase 1 (JAK1), exhibiting an IC50 of less than 5 μM. This compound demonstrates over eightfold selectivity for JAK1 compared to JAK2 and JAK3. JAK-IN-14 is valuable for research applications focused on elucidating the role of JAK1 in various inflammatory and autoimmune conditions. -
JAK Inhibitor
Lirucitinib is a selective JAK inhibitor with significant anti-inflammatory activity. It effectively inhibits the signaling of various cytokines involved in itch and inflammation, particularly those that rely on JAK1 enzyme activity, as well as cytokines related to allergic responses. This compound is valuable for research applications focused on pruritic skin diseases and associated inflammatory conditions. -
JAK2 V617F Inhibitor
JAK2-IN-10 is a potent inhibitor targeting the JAK2 V617F mutation, exhibiting an IC50 value of ≤10 nM. This compound demonstrates significant activity in suppressing the JAK/STAT signaling pathway, which is often dysregulated in various hematological malignancies. JAK2-IN-10 is suitable for research applications focused on understanding myeloproliferative neoplasms and developing targeted therapies. -
JAK Inhibitor
JAK-IN-21 is a selective and potent inhibitor of Janus kinase (JAK), demonstrating inhibitory concentrations (IC50) of 1.73 nM for JAK1, 2.04 nM for JAK2, 109 nM for the J2V617F mutant, and 62.9 nM for TYK2. This compound is useful in research applications focused on elucidating the role of JAK signaling pathways in various diseases, including hematological malignancies and autoimmune disorders. JAK-IN-21 serves as a valuable tool for studying the therapeutic potential of JAK inhibition. -
PROTAC JAK2 Degrader
SJ1008030 is a PROTAC compound designed to selectively degrade Janus kinase 2 (JAK2). This compound exhibits potent inhibitory activity against MHH–CALL-4 cell growth, with an IC50 of 5.4 nM. SJ1008030 is valuable for research applications focusing on leukemia, facilitating the study of JAK2-related pathways and therapeutic interventions. -
Negative Control of FM-381
FM-479 serves as the negative control for FM-381, a potent covalent reversible inhibitor of JAK3 that targets the unique Cys909 residue. FM-479 demonstrates no activity against JAK3 or other kinases, allowing researchers to effectively discern the specific effects of FM-381 in experimental settings. This control reagent is essential for validating experimental results in studies focused on JAK3-mediated pathways and related signaling processes. -
Tyk-2 Inhibitor
Tyk2-IN-8 is a selective inhibitor of Tyk-2, exhibiting an IC50 of 5.7 nM for TYK2-JH2 and 3.0 nM for JAK1-JH1. This compound is instrumental in investigating the role of Tyk-2 in various biological processes. Tyk2-IN-8 is particularly relevant for research focused on autoimmune diseases, enabling studies on signaling pathways involved in immune regulation and inflammation. -
Cathepsin L/JAK Inhibitor
Dual Cathepsin L/JAK-IN-1 is a dual inhibitor targeting Cathepsin L (CTSL) and Janus kinases (JAK), exhibiting IC50 values of 0.68 μM for CTSL, 337.1 nM for JAK1, 5.251 nM for JAK2, 27.29 nM for JAK3, and 172.6 nM for TYK2. This compound effectively inhibits the activation of key signaling pathways, including MAPK, NF-κB, and JAK/STAT, thereby providing substantial anti-inflammatory effects. Dual Cathepsin L/JAK-IN-1 is useful for investigating mechanisms underlying acute lung injury (ALI) and other inflammatory conditions. -
JAK1 Inhibitor
Upadacitinib tartrate tetrahydrate is a selective inhibitor of Janus kinase 1 (JAK1) with an IC50 value of 43 nM. It exhibits approximately 74-fold selectivity for JAK1 over JAK2 in assays utilizing specific cytokines. This compound is widely applicable in research focused on autoimmune disorders, providing insights into the modulation of immune responses through JAK1 inhibition. -
JAK Inhibitor
JAK1/TYK2-IN-1 is a potent dual inhibitor targeting Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), with reported IC50 values of 29 nM and 41 nM, respectively. This compound exhibits significant anti-inflammatory and immunomodulatory effects, making it a valuable tool for research related to autoimmune disorders and cytokine signaling pathways. Its ability to selectively inhibit JAK1 and TYK2 enhances its potential for studying the mechanisms of JAK-mediated signaling in various biological contexts. -
JAK Inhibitor
Peficitinib hydrobromide is a selective Janus kinase (JAK) inhibitor, exhibiting IC50 values of 3.9 nM for JAK1, 5.0 nM for JAK2, 0.7 nM for JAK3, and 4.8 nM for Tyk2. This compound is primarily utilized in research related to autoimmune diseases and inflammatory conditions, demonstrating potential therapeutic efficacy in modulating immune responses. Its oral bioavailability makes it a valuable tool for studying JAK signaling pathways in various biological models. -
JAK1/JAK2 Inhibitor
RAI-20 is a potent orally active dual inhibitor of JAK1 and JAK2, demonstrating IC50 values of 15.1 nM and 22.7 nM, respectively. This compound features favorable pharmacokinetic characteristics, including enhanced plasma stability and extended systemic exposure. In preclinical studies using a collagen-induced arthritis rat model, RAI-20 exhibited significant anti-inflammatory and anti-arthritic effects, effectively decreasing paw swelling volume and overall arthritis index. RAI-20 serves as a valuable tool for investigating the mechanisms underlying rheumatoid arthritis pathology. -
JAK3 Inhibitor
Ritlecitinib (malonate) is a selective, orally bioavailable, irreversible inhibitor of JAK3, exhibiting an IC50 of 33 nM. This compound effectively inactivates JAK3, thereby disrupting signaling pathways and downstream STAT phosphorylation triggered by common gamma chain cytokines, including IL-2 and IL-15. Ritlecitinib (malonate) is particularly useful for research into immune-related conditions, as it diminishes Th1/Th17 cell differentiation and function, and has shown efficacy in preclinical models of alopecia areata, adjuvant-induced arthritis, and experimental autoimmune encephalomyelitis. -
JAK Inhibitor
NVP-BSK805 trihydrochloride is an ATP-competitive inhibitor of Janus kinase 2 (JAK2), exhibiting IC50 values of 0.48 nM for JAK2 JH1, 31.63 nM for JAK1 JH1, 18.68 nM for JAK3 JH1, and 10.76 nM for TYK2 JH1. This compound is valuable for studying the roles of JAK family kinases in various biological processes and diseases, including inflammation, hematopoiesis, and cancer. Research applications include preclinical evaluation of therapeutic strategies targeting JAK signaling pathways. -
JAK Inhibitor
Fosifidancitinib is a potent and selective inhibitor of Janus kinase (JAK) 1 and JAK 3. This compound demonstrates significant biological activity by modulating cytokine signaling pathways, making it valuable in research related to allergies, asthma, and autoimmune diseases. Its specificity for JAK kinases supports detailed investigations into JAK-mediated mechanisms and therapeutic strategies. -
JAK Inhibitor
Nezulcitinib is a pan-Janus kinase (JAK) inhibitor with a targeted delivery system for lung tissues. This compound exhibits significant biological activity in modulating inflammatory pathways, making it a valuable tool for research on COVID-19-associated acute lung injury and impaired oxygenation. Its selective action offers potential insights into therapeutic strategies for respiratory conditions linked to JAK activation. -
JAK Inhibitor
LNK01004 is a potent JAK inhibitor, displaying strong inhibitory activity against JAK1 (IC50: 10 nM), JAK2 (IC50: <0.51 nM), and TYK2 (IC50: 1.0 nM). This compound effectively suppresses multiple cytokine-induced p-STAT signaling pathways, making it a valuable tool for the investigation of diseases, particularly atopic dermatitis. Its selective inhibition profile provides insights into therapeutic strategies targeting JAK-mediated pathways. -
JAK2/FLT3 Inhibitor
Pacritinib hydrochloride is a selective inhibitor targeting JAK2 and FLT3, demonstrating inhibitory potency against wild-type JAK2 (IC50=23 nM), the JAK2V617F mutant (IC50=19 nM), and FLT3 (IC50=22 nM) as well as the FLT3D835Y mutant (IC50=6 nM). This compound is primarily utilized in research related to acute myeloid leukemia (AML) and myelofibrosis (MF), making it a valuable tool for studying these hematological malignancies and the associated signaling pathways. -
SYK/JAK Inhibitor
Gusacitinib hydrochloride is a potent dual inhibitor of SYK and JAK kinases, demonstrating IC50 values of 5 nM, 46 nM, 4 nM, 11 nM, and 8 nM for SYK, JAK1, JAK2, JAK3, and TYK2, respectively. This compound effectively suppresses critical inflammatory pathways linked to the pathogenesis of atopic dermatitis. Gusacitinib hydrochloride is suitable for research applications involving chronic hand eczema and various cancers, including basal cell carcinoma. -
JAK-3 Inhibitor
WYE-151650 is a selective inhibitor of Janus kinase 3 (JAK-3), targeting key signaling in immune response. This compound effectively suppresses interleukin-2 (IL-2)-induced phosphorylation of signal transducer and activator of transcription 5 (STAT-5), resulting in decreased cell proliferation associated with JAK-3 activity. WYE-151650 demonstrates potential for research applications in autoimmune diseases and related immunological studies. -
JAK3 Inhibitor
EP009 is a selective inhibitor of JAK3, primarily targeting IL-2-mediated JAK3 tyrosine phosphorylation with an IC50 of 10-20 μM in Kit225 cells. This compound does not influence IL-3-induced JAK2 phosphorylation at concentrations up to 50 μM in BaF/3 cells. Notably, EP009 exhibits significant cytotoxicity in Kit225 cells, reducing cell viability with an LD50 of 5.0 μM, while leaving BaF/3 cells unaffected. This specificity makes EP009 a valuable reagent for research applications involving JAK3 signaling pathways. -
PROTAC FLT3/JAK2/BRD4 Degrader
PROTAC FLT3/JAK2/BRD4 Degrader-1 is a potent PROTAC degrader that simultaneously targets FLT3, JAK2, and BRD4, exhibiting DC50 values of 5.23 nM, 0.678 nM, and 1.17 nM, respectively. It demonstrates significant antiproliferative activity against MV4;11 cells with an IC50 of 0.79 nM, inducing apoptosis in these cells. Additionally, PROTAC FLT3/JAK2/BRD4 Degrader-1 shows marked anti-tumor efficacy in MV4;11 xenograft models in NOD SCID mice. This compound is valuable for research into acute myeloid leukemia (AML). -
JAK3/BTK Inhibitor
JAK3/BTK-IN-3 is a selective inhibitor of Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK). Targeting both JAK3 and BTK can provide synergistic effects beneficial for the therapeutic intervention of autoimmune diseases. This compound is suitable for research applications focused on elucidating the roles of JAK3 and BTK in various disease mechanisms, facilitating the development of novel treatment strategies. -
JAK Inhibitor
JAK-IN-28 is a potent JAK inhibitor that selectively targets Janus kinases, which are critical mediators of cytokine signaling pathways. This compound exhibits significant anti-inflammatory properties and is valuable for research in cancer and various inflammatory diseases. Its effectiveness in modulating JAK-mediated signaling makes it an essential tool for studying therapeutic strategies in related pathological conditions. -
JAK2/FLT3 Inhibitor
SB1578 is a selective inhibitor of JAK2 and FLT3, exhibiting IC50 values of 46 nM and 60 nM, respectively. This compound demonstrates high selectivity for other kinase targets, making it a valuable tool for research. SB1578 is particularly useful in studying non-oncological indications, such as rheumatoid arthritis, offering insights into potential therapeutic applications in inflammatory diseases. -
JAK Inhibitor
CP-352664 is a selective Janus kinase (JAK) inhibitor that specifically targets JAK3 with an EC50 value of 210 nM. This compound exhibits significant potential in research related to organ transplant rejection and autoimmune disorders, including rheumatoid arthritis. It serves as an important tool for investigating the therapeutic modulation of immune responses in various pathological conditions. -
JAK3/BTK Inhibitor
JAK3/BTK-IN-7 is a potent inhibitor targeting Janus kinase 3 (JAK3) and Bruton’s tyrosine kinase (BTK), demonstrating IC50 values of 2 nM and 14 nM, respectively. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for investigating the underlying mechanisms of rheumatoid arthritis. Its efficacy in modulating inflammatory pathways highlights its potential in related therapeutic research applications. -
JAK2/3 Inhibitor
JAK-2/3-IN-1 is a highly selective inhibitor of Janus kinase 2 (JAK-2) and Janus kinase 3 (JAK-3), exhibiting Ki values of less than 250 nM for both isoforms. This compound is relevant for research applications focused on inflammatory diseases and hematological malignancies where JAK signaling plays a crucial role. Its potency and specificity make it suitable for studying the molecular mechanisms of JAK-related pathways and evaluating potential therapeutic strategies. -
Bioactive Peptide
Jak3tide is a biologically active peptide that serves as a substrate for Janus kinase 3 (JAK3). It contains a phosphorylation site at Tyr7, making it suitable for kinase assay applications. This peptide can be utilized in various research settings to study JAK3-mediated signaling pathways and its role in cellular activities. -
JAK3 Inhibitor
JAK3-IN-16 is a covalent inhibitor of Janus kinase 3 (JAK3), targeting the enzymatic activity that regulates cytokine signaling pathways. This compound exhibits potent inhibition of JAK3, making it a valuable tool for research into immune response modulation and related therapeutic applications. JAK3-IN-16 is particularly useful in studies focused on autoimmune diseases and hematological disorders. -
JAK Inhibitor
MMT3-72-M2 is a selective inhibitor targeting Janus kinase 1 (JAK1). This compound exhibits potent inhibition of JAK1 with an IC50 value of 10.8 nM, and also inhibits JAK2, TYK2, and JAK3 with IC50 values of 26.3 nM, 91.6 nM, and 328.7 nM, respectively. MMT3-72-M2 is valuable for research in signaling pathways related to immune responses and inflammation. -
Peptide
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from amino acids 475 to 491 of the mouse JAK2 protein. This peptide serves as a substrate for the examination of JAK2 phosphorylation at tyrosine residues 8 and 9, providing insights into its regulatory mechanisms. It is valuable for studying JAK2-related signaling pathways and their implications in various cellular processes and diseases, including hematopoiesis and immune response. -
JAK Inhibitor
Peficitinib hydrochloride is a selective Janus kinase (JAK) inhibitor that effectively targets JAK1, JAK2, JAK3, and Tyk2, with IC50 values of 3.9 nM, 5.0 nM, 0.7 nM, and 4.8 nM, respectively. This compound is primarily used in research to investigate JAK-dependent signaling pathways and for studies related to inflammatory and autoimmune diseases. Its potent inhibitory activity makes it a valuable tool for exploring therapeutic options against conditions such as rheumatoid arthritis and psoriasis. -
JAK3/JAK1/TBK1 Inhibitor
CS12192 is a JAK3/JAK1/TBK1 inhibitor that modulates immune responses by inhibiting key signaling pathways involved in inflammatory processes. This compound has demonstrated efficacy in improving survival and promoting weight gain. CS12192 holds potential for research applications in graft-versus-host disease (GVHD), offering insights into therapeutic strategies for managing this condition. -
JAK2 Inhibitor
JAK2-IN-15 is a potent and selective inhibitor of JAK2, exhibiting an IC50 value of 1.17 nM. It effectively targets the JAK2-STAT signaling pathway, making it a valuable tool for investigating therapeutic strategies. In preclinical studies, JAK2-IN-15 has demonstrated significant improvements in hematocrit levels and reductions in splenomegaly in an Epoetin beta-induced mouse model. This compound is particularly relevant for research into Polycythemia Vera (PV) and related hematological disorders. -
IKKβ/JAK2 Inhibitor
EC-70124 is an orally active multikinase inhibitor that targets IKKβ and JAK2. By blocking IkB phosphorylation and the activation of STAT3 (Tyr705), EC-70124 inhibits NF-κB nuclear translocation and impedes STAT3 transcriptional activity. This compound has demonstrated the ability to reduce tumor growth and diminish cancer stem cell populations in prostate cancer cells and xenograft models, making it a valuable tool for research in prostate cancer. -
JAK Inhibitor
JAK-IN-30 is a potent and water-soluble inhibitor of Janus kinases (JAKs), exhibiting IC50 values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2. This compound demonstrates significant biological activity in modulating JAK signaling pathways, making it a valuable tool for investigating inflammatory conditions. Its applicability in research extends to the study of dry eye disease (DED) and other JAK-related disorders. -
JAK3 Inhibitor
JANEX-1 hydrochloride is a selective inhibitor of Janus kinase 3 (JAK3), exhibiting a Ki value of 2.3 μM and an IC50 of 78 μM for JAK3 inhibition. This compound does not inhibit JAK1 or JAK2, making it a valuable tool for studying JAK3-specific signaling pathways. JANEX-1 hydrochloride is suitable for research applications focused on immune responses and hematological disorders where JAK3 plays a critical role. -
JAK1 Inhibitor
JAK1-IN-20 is a selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of less than 0.5 nM, demonstrating potent inhibition of its enzymatic activity. By reducing the production of proinflammatory cytokines such as TNF-α and IL-6, JAK1-IN-20 effectively suppresses the phosphorylation of STAT3. This compound shows promise in ameliorating ulcerative colitis and serves as a valuable tool in the research of inflammatory bowel disease. -
CDK2/JAK2/FLT3 Inhibitor
Zotiraciclib hydrochloride is a novel small molecule inhibitor targeting cyclin-dependent kinase 2 (CDK2), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase 3 (FLT3). This reagent demonstrates anti-tumor activity by downregulating the Myc oncogene through CDK9 inhibition, contributing to reduced tumor growth. Zotiraciclib hydrochloride is particularly relevant for research into cancers capable of crossing the blood-brain barrier, and elevated levels of the MCL-1 protein may indicate its potential as a prognostic marker and therapeutic target in cancer studies. -
JAK2/STAT3 Pathway Inhibitor
WP1193 is a potent inhibitor of the JAK2/STAT3 signaling pathway. It effectively suppresses the phosphorylation of both JAK2 and STAT3, leading to a decrease in the expression of key stem cell markers such as CD133 and c-myc. This compound is valuable for research into glioblastoma and other cancers associated with aberrant activation of the JAK2/STAT3 pathway. -
JAK1/JAK2 Inhibitor
Momelotinib dihydrochloride is a selective JAK1/JAK2 inhibitor that also targets ACVR1, resulting in decreased Hepcidin expression which enhances iron availability for erythropoiesis. This compound has demonstrated efficacy in reducing transfusion dependency and alleviating splenomegaly associated with myelofibrosis. Its unique mechanism and biological activity make Momelotinib dihydrochloride a valuable tool for research in myelofibrosis and related hematological conditions. -
JAK3 Inhibitor
Thi-DPPY is a potent and orally active inhibitor of JAK3, exhibiting IC50 values of 62.4 nM for BTK and 1.38 nM for JAK. This compound demonstrates significant anti-proliferative effects on human bronchial epithelial (HBE) cells and possesses anti-inflammatory properties in vivo. Thi-DPPY is a valuable tool for investigating potential therapeutic applications in idiopathic pulmonary fibrosis (IPF). -
TYK2/JAK1 Inhibitor
JAK1/TYK2-IN-3 is a selective, orally bioavailable dual inhibitor of TYK2 and JAK1, exhibiting IC50 values of 6 nM and 37 nM, respectively. This compound demonstrates notable selectivity towards JAK2 and JAK3, with IC50 values of 140 nM and 362 nM, respectively. JAK1/TYK2-IN-3 is recognized for its significant anti-inflammatory effects through the modulation of TYK2/JAK1-regulated genes and the differentiation of Th1, Th2, and Th17 cells, making it a valuable tool for research in autoimmune diseases and inflammation. -
JAK Inhibitor
PF-00956980 is a reversible pan-JAK inhibitor that demonstrates inhibitory activity with IC50 values of 2.2 μM for JAK1, 23.1 μM for JAK2, and 59.9 μM for JAK3. This compound is utilized in research focusing on lung and skin inflammatory diseases, providing valuable insights into JAK signaling pathways and their role in inflammatory responses. Its broad inhibitory profile makes it a suitable tool for studying the therapeutic potential of JAK inhibition.
